Magnetic nanoparticle design for medical applications

Magnetic nanoparticles have attracted attention because of their current and potential usefulness as contrast agents for magnetic resonance imaging (MRI) or colloidal mediators for cancer magnetic hyperthermia. This contribution examines these in vivo applications through an understanding of the involved problems and the current and future possibilities for resolving them. A special emphasis is made on magnetic nanoparticle requirements from a physical viewpoint (e.g. relaxivity for MRI and specific absorption rate for hyperthermia), the factors affecting their biodistribution and the solutions envisaged for enhancing their half-life in the blood compartment and targeting tumour cells. Then, the synthesis strategies developed in our group are presented and focused on covalent platforms capable to be tailor-derivatised by surface molecular chemistry. The opportunity of using more complex oxides than conventional magnetite for controlling the in vivo temperature is also discussed.

[1]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[2]  F. Veronese,et al.  Stabilization of substances in circulation. , 1998, Bioconjugate chemistry.

[3]  Q. Pankhurst,et al.  Applications of magnetic nanoparticles in biomedicine , 2003 .

[4]  R. T. Gordon,et al.  Intracellular hyperthermia. A biophysical approach to cancer treatment via intracellular temperature and biophysical alterations. , 1979, Medical hypotheses.

[5]  Nathan Kohler,et al.  Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. , 2002, Biomaterials.

[6]  P. Moroz,et al.  Magnetically mediated hyperthermia: current status and future directions , 2002, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[7]  S. Loening,et al.  Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia , 2001 .

[8]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[9]  P Wust,et al.  Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. , 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[10]  É. Duguet,et al.  Magnetic nanoparticle design for medical diagnosis and therapy , 2004 .

[11]  H. Nowak,et al.  Magnetism in Medicine , 2006 .

[12]  Okuhata,et al.  Delivery of diagnostic agents for magnetic resonance imaging. , 1999, Advanced drug delivery reviews.

[13]  P. Wust,et al.  Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles , 1999 .

[14]  C. W. Jung.  Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.

[15]  Peter Wust,et al.  Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro , 1999 .

[16]  Wolfgang Ebert,et al.  Tissue-specific MR contrast agents. , 2003, European journal of radiology.

[17]  Etienne Duguet,et al.  A method for synthesis and functionalization of ultrasmall superparamagnetic covalent carriers based on maghemite and dextran , 2005 .

[18]  A. Vekris,et al.  Synthesis, magnetic properties, surface modification and cytotoxicity evaluation of Y3Fe5−xAlxO12 (0⩽x⩽2) garnet submicron particles for biomedical applications , 2001 .

[19]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. , 1990, Radiology.

[20]  B. Bonnemain,et al.  Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. , 1998, Journal of drug targeting.

[21]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.